Abstracts tagged "Cardiovascular"

Abstract Number: 1993 • ACR Convergence 2020
Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for cardiovascular (CV) events. While most RA patients use conventional disease-modifying antirheumatic drugs (DMARDs) such as…
Abstract Number: 0431 • ACR Convergence 2020
Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
Elizabeth Park¹, Jon Giles², Thania Perez-Recio¹, Paloma Pina³, Christopher Depender¹, Joan Bathon¹ and Laura Geraldino-Pardilla⁴, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University, New York, NY, ³Cardiac Electrophysiology, Northwestern Medicine, Chicago, IL, ⁴Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…
Abstract Number: 0864 • ACR Convergence 2020
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression in Patients with Systemic Lupus Erythematosus
Lisa Zhu¹, Manpreet Singh², Caroline Siegel³, Lori Sahakian², Jennifer Grossman⁴ and Maureen McMahon⁵, ¹University of California, Los Angeles, Van Nuys, CA, ²University of California, Los Angeles, Los Angeles, CA, ³Hospital for Special Surgery, New York, NY, ⁴University of California, Los Angeles, Sherman Oaks, CA, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) has demonstrated a wide array of beneficial effects in patients with systemic lupus erythematosus (SLE), with regard to disease activity, flare rates,…
Abstract Number: 1192 • ACR Convergence 2020
Subclinical Coronary Calcification Associated with Long-term Cardiovascular Outcomes in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth¹, Elizabeth Hernandez¹ and Matthew Budoff¹, ¹Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA
Background/Purpose: Large, multicenter studies established the strong prognostic value of coronary artery calcium (CAC) scoring in asymptomatic individuals. Increasing CAC score is an independent predictor…
Abstract Number: 1514 • ACR Convergence 2020
The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study
April Jorge¹, Xiaoqing Fu², Yuqing Zhang³, Hyon Choi⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Harvard Medical School, Boston, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁵Harvard Medical School, Boston
Background/Purpose:A major complication of systemic lupus erythematosus (SLE) is the progression of lupus nephritis (LN) to end-stage kidney disease (ESKD). Both SLE and ESKD are…
Abstract Number: 2000 • ACR Convergence 2020
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest an increased risk of venous thromboembolism (VTE) among patients with rheumatoid arthritis (RA). However, little is known about the comparative risk…
Abstract Number: 0448 • ACR Convergence 2020
Disease-related factors associated to atherosclerotic disease in axial spondyloarthritis. A mutlicenter study with 806 patients.
Inigo Gonzalez-Mazon¹, Ivan Ferraz-Amaro², Javier Rueda-Gotor³, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Mario Agudo-Bilbao³, Fernanda Genre⁶, Sara Remuzgo-Martínez⁶, Veronica Pulito-Cueto⁶, Alfonso Corrales⁷, Leticia Lera-Gómez⁶, Virginia Portilla⁶, Vanesa Calvo-Río³, Cristina Mata⁸, Vanesa Hernández-Hernández⁹, Santos Castañeda¹⁰, Esther Francisca Vicente-Rabaneda¹¹, C Fernandez-Carballido¹², M Paz Martínez-Vidal¹³, David Castro-Corredor¹⁴, Joaquín Anino-Fernández¹⁴, Juan Carlos Quevedo-Abeledo¹⁵, Carlos Rodríguez-Lozano¹⁶, C. Fernandez-Diaz¹⁷, Esther Montes-Perez¹⁸, María Luz García Vivar,¹⁹, Eva Galínez-Agirregoikoa¹⁹, Javier Llorca²⁰, Raquel López-Mejías⁶, Chamaida Plasencia²¹, Diana Peiteado²², Alejandro Balsa-Criado²³, Nuria Barbarroja²⁴, Lourdes Ladehesa-Pineda²⁵, Rafaela Ortega-Castro²⁶, Eduardo Collantes-Estévez²⁵, Ricardo Blanco⁴ and Miguel Ángel González-Gay²⁷, ¹Hospital Universitario Marques de Valdecilla, Bezana, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³H.U. Marques de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁶Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁷Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Hospital de Laredo, Santander, Spain, ⁹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ¹¹Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ¹²H San Juan, Alicante, Spain, ¹³Hospital General Universitario de Alicante, Alicante, Spain, ¹⁴Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹⁵Hospital Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁷H. Marqués de Valdecilla, Madrid, Spain, ¹⁸Diagnóstico Médico Cantabria (DMC), Santander, Spain, ¹⁹Hospital Universitario Basurto, Bilbao, Spain, ²⁰School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ²¹Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ²²Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ²³HOSPITAL UNIVERSITARIO LA PAZ, madrid, Spain, ²⁴Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁵Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ²⁶Hospital Universitario Reina Sofía, Córdoba, Spain, ²⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Cardiovascular (CV) mortality and morbidity is increased in ankylosing spondylitits (AS) due to a process of accelerated atherosclerosis. The disease-related factors involved in this…
Abstract Number: 0870 • ACR Convergence 2020
Hydroxychloroquine Is Associated with Lower Platelet Activity and Improved Vascular Health in Systemic Lupus Erythematosus
Michael Golpanian¹, Elliot Luttrell-Williams², MacIntosh Cornwell², Khrystyna Myndzar², Hanane El Bannoudi², Ashira Blazer², Stuart Katz², Nathaniel Smilowitz², Kelly Ruggles², Robert Clancy³, Jill Buyon⁴ and Jeffrey Berger², ¹New York University, New York, NY, ²New York University School of Medicine, New York, ³NYU School of Medicine, New York, ⁴Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of premature atherosclerosis and thrombosis. Hydroxychloroquine (HCQ) is widely used in the treatment of…
Abstract Number: 1193 • ACR Convergence 2020
Unsupervised Molecular Profile Clustering in the Serum of Rheumatoid Arthritis Patients Identifies Groups with Differential CV-risk SCORE: Modulation by Biological Therapies
Maria Luque-Tevar¹, Carlos Pérez-Sánchez¹, Pilar Font², Alejandra Maria Patiño-Trives¹, Montserrat Romero-Gomez², Desirée Ruiz-Vilchez², Sara Remuzgo-Martínez³, Raquel López-Mejías⁴, Iván Arias de la Rosa¹, Carmen Torres-Granados¹, María-Carmen Abalos-Aguilera¹, Rafaela Ortega-Castro², Alejandro Escudero-Contreras², Carlos Rodriguez-Escalera⁵, Jose Perez-Venegas⁶, Mª Dolores Ruiz-Montesinos⁶, Carmen Dominguez⁶, Carmen Romero-Barco⁷, Antonio Fernandez-Nebro⁸, Natalia Mena-Vazquez⁹, Jose Luis Marenco¹⁰, Julia Uceda-Montañez¹⁰, Mª Dolores Toledo-Coello¹¹, Nuria Barbarroja¹, M Angeles Aguirre², Eduardo Collantes², Miguel A Gonzalez-Gay¹² and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital Universitario de Jaen, Jaén, Spain, ⁶Hospital Universitario Virgen Macarena, Sevilla, Sevilla, Spain, ⁷Hospital Clínico Universitario, Málaga, Málaga, Spain, ⁸University of Malaga, Malaga, Spain, ⁹Hospital Regional Universitario de Málaga, Málaga, Spain, ¹⁰Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, ¹¹Hospital Universitario de Jerez de la Frontera, Cádiz, Spain, Cádiz, Spain, ¹²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander
Background/Purpose: To identify specific molecular profiles associated to the enhanced cardiovascular (CV)-risk present in Rheumatoid Arthritis (RA) patients and their modulation by biologic disease modifying…
Abstract Number: 1540 • ACR Convergence 2020
Association Between Disease Activity and Left Ventricular Systolic Function in Patients with Rheumatoid Arthritis: A Case-Control Study
Elías Abraham Rodríguez¹, Dionicio Ángel Galarza-Delgado², José Ramón Azpiri López³, Iris Jazmín Colunga Pedraza⁴, Salvador Lugo Pérez³, Itzel Corina Zárate Salinas³, Paola Fernanda Frausto Lerma⁴, Alejandra Pérez Villar⁴, Mayra Alejandra Reyes Soto⁴ and Raymundo Vera⁵, ¹Hospital Universitario "José Eleuterio González", Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Cardiology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, ⁴Rheumatology service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, ⁵Cardiology Service Hospital Universitario "José Eleuterio González", Monterrey, Mexico
Background/Purpose: Patients with Rheumatoid Arthritis(RA) have a higher prevalence of Cardiovascular Disease (CVD), which is the most common cause of death in this group. Disease…
Abstract Number: 0484 • ACR Convergence 2020
Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Receiving Tofacitinib
Christina Charles-Schoeman¹, Craig Hyde², Shunjie Guan³, Neil Parikh¹, Jennifer Wang¹, Ani Shahbazian¹, Lori Stockert⁴ and John Andrews⁴, ¹University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)‑associated enzyme with paraoxonase, lactonase, and arylesterase activities. PON1 contributes to the antioxidant properties of HDL, and…
Abstract Number: 0878 • ACR Convergence 2020
Absolute Lymphocyte Count Is Negatively Correlated with Atherosclerotic Cardiovascular Disease Risk Score and Red Cell Distribution Width in Psoriatic Arthritis and Increases with TNF-Inhibitor Therapy
Angela Gupta¹, Sofi Damjanovska², Alyssa Lange³, Brigid Wilson⁴, Taissa Bej⁴, Maya Mattar⁵, David Zidar⁶ and Donald Anthony⁷, ¹(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ²(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ³Case Western Reserve University, Cleveland, ⁴Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ⁵Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ⁶Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁷Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Absolute lymphocyte count (ALC) is a parameter that represents the number of lymphocytes (B, T, and NK cells) in the blood, and lymphopenia often…
Abstract Number: 1219 • ACR Convergence 2020
Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 Diabetes Improves the Glucose Homeostasis: Long-term Findings from TRACK Study, a Multicentre, Open-label, Randomised, Controlled Trial
Piero Ruscitti¹, Onorina Berardicurti¹, Paola Cipriani¹ and Roberto Giacomelli¹, ¹University of L'Aquila, L'Aquila, Italy
Background/Purpose: The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets by using biologic DMARDs designed for rheumatoid arthritis (RA), and IL-1…
Abstract Number: 1548 • ACR Convergence 2020
Blood Pressure, BMI and Sex Affect Optical Spectral Transmission Imaging Measurements of the Hands
Annelies Blanken¹, Conny van der Laken² and Mike Nurmohamed³, ¹Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, location Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands
Background/Purpose: Optical spectral transmission imaging (OST) is a new imaging method designed to measure inflammation in the hands of rheumatoid arthritis (RA) patients. The device…
Abstract Number: 0485 • ACR Convergence 2020
Non-obese Rheumatoid Arthritis Patients with Low Low-density Lipoprotein Have Higher Coronary Atherosclerosis Burden, Greater Plaque Progression and Cardiovascular Event Risk
George Karpouzas¹, Sarah Ormseth¹, Elizabeth Hernandez¹ and Matthew Budoff¹, ¹Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA
Background/Purpose: RA patients with low body weight incur higher mortality than obese patients. Paradoxically, RA patients in the lowest low-density lipoprotein group (LDL < 70…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].